Scholars Central

Conference abstractPublished 12 Oct 2020

Posttransplant lymphoproliferative disorders (PTLD) in kidney transplant recipients: Case report

Authors: Julia Paravizo Lello Santos

José do Rosário Vellano University, Brazil

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

We present two cases of acute abdominal surgical presentations, secondary to PTLD developing after renal transplantation. Case 1: A 45-year-old male underwent a livinghaploidentical donor renal transplantation and received immunosuppression therapy (cyclosporine, mycophenolate mofetil, and prednisolone). Nine years after transplantation his graft function was stable (creatinine 1.1 mg/dL), when presented with diffuse abdominal pain with perforation intestine signals. The pathological finding were compatible with post-transplant lymproliferative monomorphic disorder, high-grade lymphocytes of B-cell origin by their CD20 positivity and co-expression of CD10 and negative for BCL 2.In situhybridization for EBV-encoded RNA (EBER) was strongly positive (Figure 1). Patient had mTOR conversion, and sirolimus was included in the immunosuppression schedule. Case 2: A 35-year-old female was submitted to a renal transplant with HLA-distinct living related donor, receiving prednisone, cyclosporine and azathioprine. After 13 years with stable clinical/laboratorial outcomes, she was attended with small bowel obstruction symptoms. The cells in this tumour were confirmed immunohistochemically as lymphocytes of B-cell (Figures 2) origin by their CD20 (Figure 3) and CD79a, with a proliferation rate of 80% (Ki67). Sirolimus was initiated with CNI suspension. Discussion: PTLD has become an important comorbidity in kidney transplant recipients. Some studies focus on the differences between early-onset and late-onset PTLD, that is, the segregation between EBV-driven disease versus later coincidental lymphomas expected in the general immunocompetent population. The disease can occur in a wide range of locations. Minimization of immunosuppression is the mainstay of treatment after PTLD diagnosis and a multidisciplinary oncological approach is essential.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • SubjectNephrology & Urology
  • SubjectSurgery
  • BylineArticles whose byline prints “Julia Paravizo Lello Santos”